In this Issue:
Costs of SMBG provision in the UK
ABA system in type 1 diabetes treated with multiple daily insulin injections
Dietary protein on postprandial blood glucose levels in type 1 diabetes
Long-term benefits of intensive glucose control for ESRD prevention
Insulin ±metformin and risks of all-cause mortality and other outcomes
Diabetes treatments and risks of amputation, blindness, kidney failure & hyper/hypoglycaemia
Global diabetes trends since 1980
RYGB vs. lifestyle/medical intervention for type 2 diabetes
Ranolazine with glimepiride or metformin in type 2 diabetes
BI 135585, an 11β-HSD1 inhibitor, in humans
Please login below to download this issue (PDF)